POPULARITY
Categories
247 episodes with findings
107 episodes with findings
75 episodes with findings
58 episodes with findings
36 episodes with findings
23 episodes with findings
41 episodes with findings
19 episodes with findings
18 episodes with findings
15 episodes with findings
9 episodes with findings
9 episodes with findings
21 episodes with findings
13 episodes with findings
7 episodes with findings
8 episodes with findings
12 episodes with findings
5 episodes with findings
14 episodes with findings
6 episodes with findings
16 episodes with findings
14 episodes with findings
5 episodes with findings
5 episodes with findings
6 episodes with findings
8 episodes with findings
7 episodes with findings
8 episodes with findings
6 episodes with findings
6 episodes with findings
5 episodes with findings
14 episodes with findings
6 episodes with findings
5 episodes with findings
4 episodes with findings
10 episodes with findings
4 episodes with findings
6 episodes with findings
7 episodes with findings
6 episodes with findings
7 episodes with findings
12 episodes with findings
6 episodes with findings
6 episodes with findings
5 episodes with findings
6 episodes with findings
7 episodes with findings
3 episodes with findings
5 episodes with findings
4 episodes with findings
8 episodes with findings
12 episodes with findings
6 episodes with findings
8 episodes with findings
10 episodes with findings
4 episodes with findings
9 episodes with findings
4 episodes with findings
4 episodes with findings
4 episodes with findings
4 episodes with findings
9 episodes with findings
12 episodes with findings
8 episodes with findings
5 episodes with findings
3 episodes with findings
3 episodes with findings
5 episodes with findings
3 episodes with findings
3 episodes with findings
6 episodes with findings
2 episodes with findings
2 episodes with findings
3 episodes with findings
8 episodes with findings
2 episodes with findings
5 episodes with findings
5 episodes with findings
4 episodes with findings
3 episodes with findings
5 episodes with findings
5 episodes with findings
4 episodes with findings
3 episodes with findings
4 episodes with findings
3 episodes with findings
3 episodes with findings
3 episodes with findings
3 episodes with findings
4 episodes with findings
2 episodes with findings
2 episodes with findings
2 episodes with findings
7 episodes with findings
4 episodes with findings
2 episodes with findings
4 episodes with findings
3 episodes with findings
4 episodes with findings
5 episodes with findings
5 episodes with findings
3 episodes with findings
2 episodes with findings
3 episodes with findings
8 episodes with findings
3 episodes with findings
2 episodes with findings
3 episodes with findings
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels. Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said. “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.” Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas. The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/ XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition. G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment. The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes. "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes. The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November. https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/ XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. , The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say. In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries." The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours. Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy. At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy. Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells. Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially. Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells. “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release. “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification
John Maytham is joined by Francois Viljoen, systemic investigations manager at the Tax Ombud’s Office to discuss how SARS investigators failed eFiling hijacking victims. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.
Dr. Shau-Ming Wei (National Institute of Mental Health, Bethesda, MD) joins AJP Audio to discuss a replication study looking at impact of hormone addback to a hormone suppression regimen for the treatment of premenstrual dysphoric disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the October issue of the Journal. 00:34 Wei interview 02:59 PMDD 04:22 Up and downsides of hormone suppression 05:52 Hormone addback 07:15 Limitations of the current study 08:38 Further research 10:42 Kalin interview 10:58 Wei et al. 15:25 Sanacora et al. 20:07 Whittle et al. 23:06 Cooper et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org
A stark new report from HIQA has laid bare the ongoing crisis at University Hospital Limerick, warning that chronic overcrowding continues to put patient safety at risk.Minister Patrick O'Donovan gave his reaction on Limerick Today Hosted on Acast. See acast.com/privacy for more information.
Let's dive back into this Kawhi Leonard story. Pablo Torre continues to uncover even more details from this Steve Ballmer, Aspiration, Clippers, Kawhi story. It never seems to end! But now Kawhi had to answer some media questions. (19:30) The Clippers weren't done yet. A new patch deal with Rwanda? Huh? (25:10) Steve Cohen finally tweeted. What a guy. What an owner. Then we had David Stearns talk about the Mets season. And sorry Mets fans, but Carlos Mendoza is coming back. (37:30) Dolphins got a win. But, they lost Tyreek Hill, for likely a long time. Devastating injury. (44:30) NPPOD. (46:30) LeBron James met with media yesterday. Is this it for him? Learn more about your ad choices. Visit podcastchoices.com/adchoices
Let's dive back into this Kawhi Leonard story. Pablo Torre continues to uncover even more details from this Steve Ballmer, Aspiration, Clippers, Kawhi story. It never seems to end! But now Kawhi had to answer some media questions. (19:30) The Clippers weren't done yet. A new patch deal with Rwanda? Huh? (25:10) Steve Cohen finally tweeted. What a guy. What an owner. Then we had David Stearns talk about the Mets season. And sorry Mets fans, but Carlos Mendoza is coming back. (37:30) Dolphins got a win. But, they lost Tyreek Hill, for likely a long time. Devastating injury. (44:30) NPPOD. (46:30) LeBron James met with media yesterday. Is this it for him? Learn more about your ad choices. Visit podcastchoices.com/adchoices
Too many organizations treat crisis simulations and tabletop exercises as the finish line, when in reality they're just the starting point. In this episode, Rob Burton explores why the real value lies in what comes after the exercise: prioritizing findings, assigning ownership, keeping leadership engaged, and measuring improvement. Rob shares common challenges resilience leaders face,... The post Closing the Gap: Turning After-Action Findings into Real Resilience appeared first on PreparedEx.
We take look at new figures contained in 2024 ‘Local Authority Performance Indicator Report' from National Oversight and Audit Commission. The findings all to discuss with Michael McCarthy, Chair of the National Oversight and Audit Commission.
In this episode, we speak with Dr. Kathrin Zangerl, a pediatrician and global health researcher at the Heidelberg Institute of Global Health, about why children must be at the center of climate change adaptation.Drawing on her clinical experience in Germany and Nepal, as well as her recent Lancet Child & Adolescent Health article analyzing 160 national adaptation plans, Kathrin explains why children are disproportionately impacted by climate change yet remain largely absent from climate policy. She reflects on the political and justice dimensions of this gap, highlights what meaningful child participation could look like, and shares ideas for how practitioners and the public can demand more child-centered approaches.Why are children more vulnerable to climate change? What happens when they are excluded from national adaptation strategies? And how can their rights and voices be embedded in climate governance? Join us as we explore these questions and more.
Hometown Radio 09/26/25 6p: The City of SLO rejects recent Grand Jury findings
Send us a textJoin your favorite truth seekers (if you can get past the horrible background noise lol!) as they break down the latest relevant news stories and discuss Sabrina Wallace and her findings around the WBAN Support the show@truthorpropaganda Truthorpropaganda@gmail.com
Azets Ireland has unveiled new data which reveals that 60% of Irish businesses are using AI in some form as part of everyday operations. AI adoption grows among Irish firms The survey of 119 firms across Ireland in May 2025 reveals how Irish SMEs are using technology to future-proof their operations amid the accelerating digital transformation. Findings reveal growing rates of adoption of AI tools and technology, with the number of organisations using AI across their organisation every day rising by 11% since last November. Despite growing levels of adoption, a significant proportion of firms remain at an early stage on their AI journey. 21% of firms have not yet integrated AI in their business, while 19% of firms are researching the technology but have yet to implement it within operations. Only 1% of firms consider themselves to be at the forefront of AI adoption and innovation in their sector. Smaller firms lagging behind There are also signs of a correlation between company size and adoption, with smaller companies struggling to keep pace with larger counterparts. 71% of micro businesses (10 employees or less) have yet to adopt AI within operations, compared to only 12% of large organisations. The Finance sector has the highest level of AI adoption, with 76% of organisations having implemented AI in some capacity. This compares to 54% of firms in the construction sector and 53% of firms in the retail sector. Cybersecurity tops business priorities Findings show that cybersecurity is the top business priority for firms in Ireland, amid the rapidly evolving AI landscape. Data on key growth indicators show that firms expect to significantly strengthen cybersecurity over the next 12 months, scoring a projected change in capabilities at 6.7 out of 10. Digitalisation and future turnover follow at 6.4 out of 10, indicating an elevated focus on growth and technology investment. Irish firms experience a lower level of cybersecurity incidents across Northern Europe The results show that Irish organisations experienced the lowest level of cybersecurity incidents (30%) across the six northern European countries surveyed. This compares to an average of 38% across the UK, Denmark, Finland, Norway and Sweden. Only 8% of Irish firms reported multiple cyber incidents across the year, demonstrating a high level of cyber resilience across the Irish business community. The construction sector experienced the highest average rate of cyber incidents, with 45% reporting at least one incident over the past 12 months. This is followed by the finance sector, with 43% of surveyed firms reporting a minimum of one incident. More than 1 in 3 (37%) medium-sized businesses reported a cyber incident over the past 12 months. Commenting on the findings, Neil Hughes, CEO of Azets Ireland, said: "In an era of heightened economic and trade volatility, business leaders need to navigate their organisation through short-term turbulence while planning effectively for the future. "Many SMEs in sectors such as hospitality, retail, and other family-owned businesses are under pressure as a result of the rising cost of business and need greater support if they are to grow and thrive into the future. Reducing the cost and regulatory burden on these businesses must be a priority in the months ahead. "Despite these challenges, our findings show that leaders are taking decisive steps to future-proof their organisation and drive growth from harnessing the power of AI to strengthening cybersecurity. It's clear that leaders increasingly recognise the potential of AI to enhance productivity and efficiency across their organisation and are embracing the technology in their business. "Not every business has the resources to keep pace with the rapid pace of innovation. Our findings show that small, owner-managed businesses in particular are struggling to advance innovation and embrace AI tools and technology. With a growing skills gap at many of these firms, it's crucial that d...
This week we talk to LCP partner Cat Drummond about the latest developments in capital modelling for general insurers. We discuss: • Findings from LCP's latest market research and benchmarking, covering both technical developments, process and resourcing issues • Key challenges for insurers, from soft markets to regulatory expectations • How insurers are reflecting changing geopolitical and climate risks in their capital models
Join Badlands Media for special coverage of President Trump announcing significant medical and scientific findings for America's children
POTUS delivers a major announcement that's sending shockwaves through the medical and political world — unveiling government findings suggesting a possible link between Tylenol use during pregnancy and autism. Speaking at the White House with HHS Secretary RFK Jr., Trump says the FDA will issue new guidance urging caution for expectant mothers and is promoting additional research, including the use of leucovorin as a potential treatment for some autism symptoms. Pags breaks down the press conference and why it matters. Then, Trazy Beanz joins the program to cut through the noise. A respected writer who's worked with MAHA, she explains what this announcement really means for families, how the medical establishment is reacting, and why this could reshape the autism conversation moving forward. It's a deep, fact-driven conversation you won't want to miss. Learn more about your ad choices. Visit megaphone.fm/adchoices
Hometown Radio 09/22/2025 4p: The City of SLO rejects recent Grand Jury findings
Goldylocks Productions presents Joyful Findings with Melissa ParksMelissa Parks is an Earth Angel, a talented Psychic Trance Medium, Angelic Guided Healer, Reiki Master, Spiritual Advisor and Spiritual Teacher. As a child she was able to see and communicate with the Spirit World but was shut down and told to ignore her gifts. Most of her life was filled with hurt, anger, and pain. It wasn't until a “voice” told her she must forgive her childhood abuser that her heart had truly opened, and her Spiritual Journey began.Once she embraced her True Self and her connection to God's Divine Beings, she understood her life's plan. She now spreads Love and Light, giving Guidance and Healing to all who seek it. Whether in a reading or healing session she opens to Past Loved Ones, Angels, Guides, and many Multi-Dimension Healers to bring forth powerful messages of Guidance and Healing.http://www.iammelissaparks.com Melissa's Sponsors: Marcia Morse with Feng Shui My SpaceFeng shui literally translates from Chinese as "wind" (feng) and water ("shui"). It's the art of arranging buildings, objects, space, and life to achieve harmony and balance. The philosophy of feng shui is the practice of arranging the pieces in living spaces in order to create balance with the natural world. The goal is to harness energy forces and establish harmony between an individual and their environment. Contact Feng Shui Specialist, Marcia Morse, to assist you in bringing in more Harmony and Peace into your home, property, or business space! Marcia is also a Realtor and can assist you in finding your New Home in the Sarasota, Florida area.https://www.fengshuimyspace.com http://www.sarasotasunset.com https://lolablueliving.com ~ 15% off, ends September 30 at midnight ET. Enter code: peace15Goldylocks Productions: http://www.goldylocksproductions.com Receive links and updates for our Shows, Special Events and Sales! Subscribe to The Goldylocks Zone Blog: https://www.whitesagewoman.me Join us on Telegram: https://t.me/goldylocksproductions Hosted on Acast. See acast.com/privacy for more information.
Goldylocks Productions presents Joyful Findings with Melissa ParksMelissa Parks is an Earth Angel, a talented Psychic Trance Medium, Angelic Guided Healer, Reiki Master, Spiritual Advisor and Spiritual Teacher. As a child she was able to see and communicate with the Spirit World but was shut down and told to ignore her gifts. Most of her life was filled with hurt, anger, and pain. It wasn't until a “voice” told her she must forgive her childhood abuser that her heart had truly opened, and her Spiritual Journey began.Once she embraced her True Self and her connection to God's Divine Beings, she understood her life's plan. She now spreads Love and Light, giving Guidance and Healing to all who seek it. Whether in a reading or healing session she opens to Past Loved Ones, Angels, Guides, and many Multi-Dimension Healers to bring forth powerful messages of Guidance and Healing.http://www.iammelissaparks.com Melissa's Sponsor: Marcia Morse with Feng Shui My SpaceFeng shui literally translates from Chinese as "wind" (feng) and water ("shui"). It's the art of arranging buildings, objects, space, and life to achieve harmony and balance. The philosophy of feng shui is the practice of arranging the pieces in living spaces in order to create balance with the natural world. The goal is to harness energy forces and establish harmony between an individual and their environment. Contact Feng Shui Specialist, Marcia Morse, to assist you in bringing in more Harmony and Peace into your home, property, or business space! Marcia is also a Realtor and can assist you in finding your New Home in the Sarasota, Florida area.https://www.fengshuimyspace.com http://www.sarasotasunset.com https://lolablueliving.com ~ 15% off, ends September 30 at midnight ET. Enter code: peace15Goldylocks Productions: http://www.goldylocksproductions.com Receive links and updates for our Shows, Special Events and Sales! Subscribe to The Goldylocks Zone Blog: https://www.whitesagewoman.me Join us on Telegram: https://t.me/goldylocksproductions Hosted on Acast. See acast.com/privacy for more information.
Men are 40 per cent more likely to die prematurely than women, while 97 per cent of GPs say they saw male patients presenting with suicidal behaviour in the past year. That's according to the “Real Face of Men's Health” report ahead of Movember, and joining Newstalk Breakfast to discuss the findings is Denis McCauley, GP and former President of the Irish Medical Organisation and Coroner for the District of Donegal.
Movember's Real Face of Men's Health report draws on new research to reveal a concerning picture of men's health in Ireland The report findings show men in Ireland are dying too young, from largely preventable causes; two in five of all male deaths are premature under the age of 75 and men are 40% more likely to die prematurely across the five leading causes of premature death. To discuss these findings Ivan was joined by Cliona Fitzpatrick, Director of Policy and Evidence at Movember.
President Donald Trump will sign the TikTok deal with China this week, a senior White House official said on Monday. Under the deal, Oracle will serve as the security provider, overseeing how U.S. user data is stored within Oracle's systems and how content recommendation algorithms operate.Trump also said his administration would make an announcement about its autism findings on Monday, though he declined to offer specifics. Autism diagnoses in the United States have increased significantly since 2000. Health Secretary Robert F. Kennedy Jr. has said that the United States is in the grip of an “autism epidemic” fueled by “environmental toxins.”
Leading hiring platform IrishJobs has today published new data, revealing that nearly 8 in 10 employers in Ireland are using AI in the hiring process. Recruiters report that AI tools are helping to enhance productivity and enabling more efficient hiring. The IrishJobs Hiring Efficiency survey gathered insights from 475 recruiters and 824 job seekers in Ireland to identify changing attitudes and actions on hiring processes in a fast-evolving labour market. Findings from the survey reveal that 78% of recruiters in Ireland are using AI at some point in their recruitment process to enhance productivity. Adoption of AI among recruiters has increased by 50 percentage points over the past 12 months. 28% of employers reported using the technology in recruitment in August 2024, according to previous research by IrishJobs. Recruiters in Germany, the UK, and Austria also took part in the research, with results indicating that Irish recruiters are following a similar trajectory to international HR professionals regarding the adoption of AI. Over half of employers in Germany (60%) use AI in their hiring processes, while 77% of recruiters in the UK report using the technology to boost productivity and efficiency. In Austria, more than two-thirds of recruiters (66%) reported leveraging AI to support recruitment activities. Impact of AI 52% of recruiters in Ireland report that manual administrative tasks take up too much time in their everyday role and slow down the hiring process. The use of AI tools and technology is having a direct impact on reducing the time spent on these tasks and streamlining the hiring process. Writing and publishing job adverts (28%) is the top way in which recruiters are using AI to automate the recruitment process and enhance productivity. Reviewing job applications and CVs (23%) is the second most frequent use of AI among recruiters. This is followed by preparing and sending offer/contract documents (17%). 13% of employers are using AI technology to conduct interviews. Despite the rapid growth in AI adoption, a sizable minority of recruiters remain uncertain about the adoption and implementation of the technology in operations. 19% of recruiters reported that their current IT systems do not support integration of AI tools. Candidate dissatisfaction with recruitment processes The survey reveals several factors that are affecting hiring success, including the length of recruitment processes and the number of stakeholders involved. 23% of job candidates report that there are too many steps involved in the hiring process and drop out before it is complete. Overall, more than 1 in 4 job candidates who apply for a role do not complete the hiring process. Many employers are considering reducing the number of interviews in response to candidate dissatisfaction, with 36% of HR leaders admitting there are now too many interviews in the hiring process. A further 44% of employers call out the need for quicker internal processes, saying it takes too long to receive feedback from hiring managers. Commenting on the findings, Christopher Paye, Country Director of The Stepstone Group Ireland with responsibility for IrishJobs, said: "The Irish economy is set to face a new period of elevated economic uncertainty over the coming months, prompted by the introduction of international trade tariffs. However, despite this heightened volatility, the outlook for the labour market remains positive, with Davy recently forecasting that the workforce will grow by 2-3 per cent in 2025, while recent data from the CSO reported that the number of people employed in the state has risen above 2.8 million for the first time. This resilience will mean that many employers in Ireland continue to navigate a highly competitive market for talent and face skills shortages across various sectors. The IrishJobs Hiring Efficiency survey provides a timely insight into the opportunities and challenges facing recruiters in this evolving environment. It's clear...
In this episode, Dr. David Jockers explains the critical role protein plays in burning fat and building muscle. You'll learn how protein stabilizes blood sugar, supports brain function, and helps maintain lean body mass as you age. He also highlights how protein reduces cravings and promotes fat burning, with a focus on amino acids like leucine for muscle growth. Plus, discover how protein boosts energy and mental clarity. Dr. Jockers shares practical tips on protein intake based on body weight and activity level, emphasizing the benefits of eating within a restricted time window. In This Episode: 00:00 Introduction to Protein and Health Risks 00:20 Podcast Welcome and Episode Overview 02:53 Importance of Protein for Health 04:34 Protein Types and Their Benefits 05:36 Leucine Threshold and Protein Intake Recommendations 11:26 Protein Intake by Weight and Meal Timing 17:10 Conclusion and Final Thoughts Struggling with stress, low energy, or poor sleep? Magnesium Breakthrough is designed to help calm your mind, enhance focus, and improve sleep quality with all seven forms of magnesium. Take advantage of an exclusive offer by visiting bioptimizers.com/jockers and using the promo code Jockers at checkout to save 10%. Don't forget to subscribe for even more discounts and free gifts with your monthly supply! If you're serious about reducing your toxic load, I highly recommend upgrading to the P600 ceramic cookware. It's 100% free from Teflon, PFAS, and plastic coatings, ensuring a non-toxic cooking experience. Right now, you can get it for 50% off, plus an extra 20% off with the code SAFE20 at checkout! Don't miss this limited-time offer—head to chefsfoundry.com/jockers to claim your discount today! Support your skin from the inside out with Clearstem, the acne brand that connects internal and external skincare without pore-clogging ingredients. Pair their best-selling Mind Body Skin hormonal acne supplement with Clearstem's clinically effective topicals for results that last. Get 15% off your order today at clearstem.com/drjockers using code DRJOCKERS at checkout. “Protein helps stabilize blood sugar, boost energy, and improve brain function — it's crucial for overall health!” ~ Dr. Jockers Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio Resources: Use code JOCKERS at bioptimizers.com/jockers to save 10% Use code Safe20 at chefsfoundry.com/jockers Get 15% off your order today at clearstem.com/drjockers using code DRJOCKERS Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/
We've all had bad bosses.We might have even been one. At the very least, we've probably let people down who counted on us.We all carry burdens from our past that show up in how we lead. And we're all confronting systems that foster toxic workplace cultures where overwork and blurred boundaries are the norm, spaces that don't feel safe or generative, and where there is little to no accountability.The question we face is simple, but urgent: How do we want to lead?Our leadership can reinforce toxic systems and norms. Or we can learn to recognize our own burdens and do the work to become more aware, adaptable, and flexible. We can create spaces where people feel seen, heard, and valued, even when systems feel unstable or unfair.Because leading is about deciding, in every moment, whether we respond from our burdens or from our values. And my guest today helps us reflect on those choices and decide how we want to lead through her own lived experiences with bad bosses. Mita Mallick is a Wall Street Journal and USA Today bestselling author who is on a mission to fix what's broken in our workplaces. She's a corporate change maker with a track record of transforming businesses and has had an extensive career as a marketing and human resources executive. Mallick is a highly sought-after speaker who has advised Fortune 500 companies and start-ups alike. She is a LinkedIn Top Voice and was named to the Thinkers 50 Radar List. She's a contributor to Harvard Business Review, Fast Company, Adweek, and Entrepreneur. Mallick has been featured in The New York Times, The Wall Street Journal, The Washington Post, Time Magazine, Forbes, Axios, Essence, Cosmopolitan Magazine and Business Insider.Listen to the full episode to hear:Three scenarios where leaders commonly shift into being bad bossesKey reasons why we tolerate bad bosses and what we can do to shift the cultureWhy Mita's 13 archetypal bad bosses persist in our workplacesWhy leaders have to invest time and connection in their team members if they want to retain themWhy another executive coaching program will not fix a truly bad bossThe number one skill leaders can focus on to become a better bossWhy corporate America needs more humility and vulnerabilityLearn more about Mita Mallick:WebsiteConnect on LinkedInReimagine Inclusion: Debunking 13 Myths to Transform Your WorkplaceThe Devil Emails at Midnight: What Good Leaders Can Learn from Bad BossesLearn more about Rebecca:rebeccaching.comWork With RebeccaThe Unburdened Leader on SubstackSign up for the weekly Unburdened Leader EmailResources:EP 102: Toxic Leadership: The True Cost of Workplace Trauma with Mita MallickGive and Take: A Revolutionary Approach to Success, Adam GrantThe Fearless Organization: Creating Psychological Safety in the Workplace for Learning, Innovation, and Growth, Amy C EdmondsonThe Normalization Of Corruption In Organizations, Blake E. Ashforth and Vikas AnandManaging to be ethical: Debunking five business ethics myths, Linda Klebe Treviño and Michael E. BrownExamining the Link Between Ethical Leadership and Employee Misconduct: The Mediating Role of Ethical Climate, David M. Mayer, Maribeth Kuenzi, Rebecca L. GreenbaumThe Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma, Bessel van der Kolk M.D.The Pocket Guide to the Polyvagal Theory: The Transformative Power of Feeling Safe, Stephen W. PorgesPrimal Leadership: Unleashing the Power of Emotional Intelligence, Prof Daniel Goleman PH D, Richard E Boyatzis, and Annie McKeePsychological Conditions of Personal Engagement and Disengagement at Work, William A. KahnEmotional Intelligence: Theory, Findings, and Implications, John D. Mayer, Peter Salovey, David R. CarusoWorking with Emotional Intelligence, Daniel GolemanThe 5Ds of Bystander Intervention - Right To BeEP 52: Charlie Gilkey: Leading With What Matters MostEP 85: Team Habits: Redefining Workplace Dynamics with Charlie GilkeyBig Magic: Creative Living Beyond Fear, Elizabeth GilbertThe Anxious Achiever: Turn Your Biggest Fears Into Your Leadership Superpower, Morra Aarons-MeleSia - UnstoppableThe SopranosBreaking BadFresh Off the BoatThe Fresh Prince of Bel Air
https://offsec.blog/budgetIn this episode, we're tackling an often-overlooked opportunity: using pentest results to secure more budget for security initiatives. Too many organizations run a pentest, file the report away, and move on without leveraging it for strategic value. We'll break down how to translate findings into business language, influence leadership, and turn vulnerabilities into funding for better defenses.Blog: https://offsec.blog/Youtube: https://www.youtube.com/@cyberthreatpovTwitter: https://x.com/cyberthreatpov Follow Spencer on social ⬇Spencer's Links: https://go.spenceralessi.com/links Work with Us: https://securit360.com
Your Natural Dog with Angela Ardolino - Formerly It's A Dog's Life
In this episode of Your Natural Dog with Angela Ardolino, Angela and Carter sit down with Dr. Joel Ehrenzweig, veterinarian, researcher, and founder of Veterinary Health Research Centers — to talk about the groundbreaking Senior Dog Study they've been running together for the past year. Dr. Ehrenzweig shares why he shifted from a strictly pharmaceutical approach to fully embracing natural medicine late in his career. Angela, Carter and Dr. Ehrenzweig discuss how the Senior Dog Study is helping to validate what holistic practitioners have known for years: that functional mushrooms and natural adaptogens can potentially make a real difference in cognitive health, quality of life, and emotional connection for senior dogs.If you have an aging pup and have ever been told “there's nothing we can do,” this episode will give you hope, real data, and real-life stories showing that there are options. Learn more about the Senior Dog Study. Episode RecapLaunching the Senior Dog Study – Carter shares how they recruited a diverse group of senior dogs experiencing cognitive decline—many from families who believed they had no options left—then tracked behavior, activity, and sleep to build a data-backed picture of progress over the course of the study. (00:31)Validating Centuries of Natural Medicine – Angela shares how rescuing senior dogs inspired her to prove that natural approaches—real food, hemp, mushrooms, and adaptogens—can help aging pets thrive without relying on pharmaceutical “longevity drugs.” Dr. Ehrenzweig reflects on his shift from a strictly pharmaceutical mindset, describing how client feedback opened his eyes to alternative options and why he was intrigued to join this groundbreaking study. (02:46)Rethinking Canine Cognitive Decline – Dr. Ehrenzweig explains why a CCD diagnosis shouldn't be seen as “the end” for senior dogs, noting that it develops gradually and shares many similarities with human dementia and Alzheimer's. He describes the challenge of studying such a complex condition and the promise of finding better options beyond pharmaceuticals. Dr. Joel expresses hope that demonstrating improvement in dogs could pave the way for better, more natural options for humans facing cognitive decline in the future. (08:10)The Power of Whole-Plant Medicine & Synergy – Angela shares why her mission is to create pure, whole-plant and mushroom formulas rather than isolated compounds, emphasizing that nature's ingredients work best together. Combining adaptogens like Lion's Mane, Reishi, Cordyceps, Ashwagandha, and Bacopa Monnieri creates a synergistic effect—targeting multiple aspects of cognitive decline and delivering the results seen in the Senior Dog Study. (11:55)Measuring the Impact of Mushrooms & Adaptogens on CCD – Carter explains how the synergistic blend of Lion's Mane, Reishi, Cordyceps, Ashwagandha, and Bacopa Monnieri for dogs was designed to address multiple aspects of cognitive decline, from calming the nervous system to supporting neuroprotection and brain oxygenation. To capture these effects, the team used detailed questionnaires and scoring systems to track behaviors like nighttime waking, disorientation, and social engagement—finding that while every dog's response is different, the combination consistently improved quality of life across a wide range of cases.(14:44)Recognizing the First Signs of CCD – Dr. Joel explains that one of the earliest and most telling signs of canine cognitive decline is a shift in sleep patterns—dogs sleeping more during the day, then pacing or appearing restless at night. With wearable collars, pet parents, and researchers, can now track movement and sleep 24/7, giving an objective view of these changes. (20:01)Real-Life Transformations from Mushrooms & Adaptogens – Angela shares moving stories of senior dogs who were scheduled for euthanasia but experienced dramatic turnarounds after starting on these mushrooms & adaptogens—regaining mobility, focus, and connection with their families in just days. Dr. Joel, a seasoned veterinary researcher with over 15 years of experience, admits he had never seen natural ingredients work this quickly and effectively, reinforcing just how extraordinary these study results have been. (26:22)Beyond Anecdotes, Real Evidence from the Senior Dog Study – Carter and Dr. Joel emphasize that the Senior Dog Study is more than just testimonials. By combining real-time collar data that tracks sleep, wake cycles, and activity with caregiver questionnaires and even blood biomarkers like BDNF and CRP, they've created an objective, data-backed picture of how dogs are responding. Dr. Joel notes that even when improvements vary, simply slowing decline can be a meaningful win for families — and in many cases, the results are dramatic, with dogs showing better engagement, calmer behavior, and restored quality of life. (32:42)Episode Resources:The Study: Prospective Evaluation of a Mushroom Derived Nutraceutical in Dogs with Cognitive DeclineLearn more about the Senior Dog StudyWant to be a part of the Senior Dog Study? More on Mushrooms & Adaptogens for Canine Cognitive DysfunctionVeterinary Health Research CentersDownload Angela's Resources at AngelaArdolino.com/podcast-downloadsHave a question about your pet that you want answered on the podcast? Email us at Carter@yournaturaldog.com Visit Angela Ardolino's website for more holistic pet health education: www.AngelaArdolino.comFollow Your Natural Dog on Facebook and Instagram and if you want to see what Angela is up to, follow her on Facebook or join our CBD & Holistic Pet Advice Facebook Group.
An independent, international commission attached to the UN’s Human Rights Council released its report this week, accusing Israel of an ongoing genocide against Palestinians in Gaza. The commission said statements made by Israeli authorities are “direct evidence of genocidal intent.” Nick Schifrin has two views on the report from Craig Mokhabir and Dr. Eran Shamir-Borer. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy
An independent, international commission attached to the UN’s Human Rights Council released its report this week, accusing Israel of an ongoing genocide against Palestinians in Gaza. The commission said statements made by Israeli authorities are “direct evidence of genocidal intent.” Nick Schifrin has two views on the report from Craig Mokhabir and Dr. Eran Shamir-Borer. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy
In this Healthed lecture, A/Prof Nicole Goh discusses the current state of play of the screening program and the likelihood of detecting non-lung cancer abnormalities. Importantly, she also presents the recommended management of the different incidental findings in the lung or in the surrounding organs or tissues - whether to leave them, monitor them or treat them. See omnystudio.com/listener for privacy information.
The Evidence Based Chiropractor- Chiropractic Marketing and Research
A new study shows that more degenerative changes on cervical MRIs actually mean less severe headaches in patients with neck pain. So, if you or your patients are stressing over how bad their imaging looks, it's time to rethink that. The big takeaway? Imaging findings don't dictate the future—holistic care, communication, and proactive strategies make the real difference.Episode Notes: Association between cervical MRI findings and patient-reported severity of headache in patients with persistent neck painLeander Tables- Save $1,000 on the Series 950 Table using the code EBC2025 — their most advanced flexion-distraction tablePatient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!
Dr Stephanie Menko joins Ethics Talk to discuss her article, coauthored with Drs Michael J. Luke and Aditi Vasan: “How Should Clinical Teams Integrate Findings From Social Needs Screenings Into Children's Care Plans?” Recorded June 27, 2025. Read the full article at JournalOfEthics.org
Full article: Out-of-the-Box Large Language Models for Detecting and Classifying Critical Findings in Radiology Reports Can LLMs help radiologists handle large volumes of critical findings requiring communication and tracking? Pranjal Raj, MD, discusses the AJR article by Talati et al. exploring the optimization and performance of LLMs in detecting and classifying radiology critical findings.
At the Society of Hematologic Oncology 2025 Annual Meeting, CancerNetwork® spoke with a variety of experts about notable clinical developments and trial results across the hematologic oncology landscape. Throughout the meeting, clinicians and researchers discussed the latest data and initiatives in myelofibrosis, multiple myeloma, lymphoma, and other types of blood cancer. Francesca Palandri, MD, PhD, an adjunct professor in the Department of Medical and Surgical Sciences at the University of Bologna in Bologna, Italy, shared insights from a session focused on exploring predictive markers for the efficacy of ruxolitinib (Jakafi) among patients with myelofibrosis.1 Noting variance in response rates as well as possibilities of disease progression or treatment discontinuation associated with ruxolitinib, Palandri emphasized the importance of assessing predictors of response to better orient clinical decision-making strategies regarding the agent's use. She also highlighted how factors such as cytopenic phenotype, higher peripheral blast counts, and higher burden of disease may impact response rates and survival among patients. Additionally, Sundar Jagannath, MD, a professor of Medicine specializing in hematology and medical oncology at the Icahn School of Medicine at Mount Sinai and The Tisch Cancer Institute, spoke about his presentation on potentially defining a cure in the management of multiple myeloma.2 He described the importance of “chang[ing] the dialogue” in multiple myeloma to give hope to patients and encourage physicians to engage in patient care more optimally. By defining a cure in multiple myeloma, Jagannath stated, it may be possible to offer more finite durations of treatment and stop therapy with the confidence that patients will not relapse. Finally, Adam J. Olszewski, MD, an associate professor of medicine at The Warren Alpert Medical School of Brown University, discussed his work on the phase 3 SUNMO trial (NCT05171647).3 Findings from this presentation showed that mosunetuzumab-axgb (Lunsumio) plus polatuzumab vedotin-piiq (Polivy; M-Pola) reduced the risk of progression or death by 59% vs rituximab (Rituxan) with gemcitabine and oxaliplatin (R-GemOx) in relapsed/refractory large B-cell lymphoma (LBCL). Olszewski also outlined next steps for refining treatment strategies in this patient population. References Palandri F. Predictive markers for ruxolitinib in MF. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Jagannath S. Is it time to say “CURE” in multiple myeloma? Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Westin J, Zhang H, Kim W, et al. Mosunetuzumab plus polatuzumab vedotin is superior R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the phase III SUNMO trial. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Abstract ABCL-1492.
The West Virginia Dept. of Human Services has released the results of its statewide listening tour. And we'll preview the latest Us & Them edition, which takes a look at this country's criminal justice system and what it would take to make it stronger for all. The post Findings From Child Welfare Tour And Rebuilding Justice In A Divided America, This West Virginia Morning appeared first on West Virginia Public Broadcasting.
Believe it or not, but Illinois had a tropical climate at one point. Recently, scientists at the University of Missouri have been able to confirm that 300 million years ago, Illinois was much more tropical than it is now.Two of the lead authors of the study join the program. The 21st Show is Illinois' statewide weekday public radio talk show, connecting Illinois and bringing you the news, culture, and stories that matter to the 21st state. Have thoughts on the show or one of our episodes, or want to share an idea for something we should talk about? Send us an email: talk@21stshow.org. If you'd like to have your say as we're planning conversations, join our texting group! Just send the word "TALK" to (217) 803-0730. Subscribe to our podcast and hear our latest conversations. Apple Podcasts: https://podcasts.apple.com/us/podcast Spotify: https://open.spotify.com/show/6PT6pb0 Find past segments, links to our social media and more at our website: 21stshow.org.
AP correspondent Haya Panjwani reports on signs of life outside Earth.
This week, Dr. Joel Kahn dives into surprising results from recent medical research. The most eye-opening? Women recovering from a heart attack with relatively preserved heart function were found to have higher mortality risk when discharged on beta-blockers — a finding that challenges 40 years of clinical practice. Dr. Kahn urges listeners to discuss these results with their own healthcare teams. Other unexpected studies are highlighted too, including new insights on taurine, spermidine, meal timing, ketogenic diets, aspirin therapy, and even sugar substitutes. Special thanks to igennus.com — use discount code DrKahn for savings.
On this episode we were joined by special guest physical therapist Alec Hyde from Bridge PT & Performance! Microscopic Magnetic Resonance Imaging Comparing Asymptomatic and Symptomatic Ulnar Collateral Ligament Injuries in Baseball Players Hoshika S, Matsuki K, Takeuchi Y, et al. Am J Sports Med. 2024;52(9):2314-2318. doi:10.1177/03635465241259472 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux
Joyce discusses concerning details following an investigation surrounding the Biden Administrations use of an autopen. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Kayla Brunn breaks down the Consumer Health Index, designed to track consumer demand “in real time.” Based on sentiment and unemployment data her firm gathers, they have created a tool to help investors get insight into consumer behavior and predict trends. Kayla explains how she thinks the index can be used and what it is helpful for.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about
The nonpartisan, public policy organization, Leaders for a Better Louisiana, recently released its latest Louisiana Fact Book. It's a list of 35 indicators over five key areas used to measure the state's overall wellbeing. The organization's chief policy officer, Barry Erwin, joins us to discuss this year's slight upward trend.The documentary “City of A Million Dreams - Parading for The Dead In New Orleans” explores the history and evolution of the New Orleans jazz funeral. That final goodbye is a mix of grief and joy, sadness and elation, weeping and second line dancing. Director Jason Berry joins us to discuss the making of the film, and how viewers can watch on Louisiana Public Broadcasting.Two decades after Hurricane Katrina, the city of New Orleans still has plenty of vacant lots, especially in the majority Black neighborhood of the Lower Ninth Ward. After the storm, Black New Orleanians struggled to return to their land and rebuild their homes, in part, because of the way the city and the state handled recovery efforts. As the coastal desk's Eva Tesfaye reports, one artist has navigated a bureaucratic city program to reclaim her family's land, with the help of her community. —Today's episode of Louisiana Considered was hosted by Karen Henderson. Our managing producer is Alana Schreiber. We receive production and technical support from Garrett Pittman, Adam Vos and our assistant producer, Aubry Procell. You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App and wherever you get your podcasts. Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!
Russ Hosmer, a U.S. Marine Corps veteran, certified life coach, former national-champion bodybuilder, and founder of Constant Progression, an online life coaching and personal development platform serving clients worldwide, joins Discover Lafayette to discuss his mission to help others reach their full potential. Russ grew up in New Jersey, just outside of New York City. At 17, his parents retired and moved to Alabama. He studied at Jacksonville State University and worked in health club turnarounds: “We found the gyms and the health clubs that were in the red, and we brought them into the black. We got the management together, the business side of it, and got them better and rolling.” Russ was a bodybuilder alongside business: “I was a state champion when I was a teenager… top five in the national championship. I was a national champion twice. Two times. Two years in a row as the first one to ever do that.” That era cemented discipline: “I was blessed. I was doing what I love… when you do that, you don't ever work a day in your life.” Choosing the Marines, Special Operations, and What Service Really Looked Like “My family is Marine Corps. My grandfather was a WWII veteran and my brother was a Marine… it was almost like, well, I have to do that.” He enlisted on a whim, calling it “probably the greatest decision of my life.” Boot camp at Parris Island: “They start drilling leadership principles into you the day you get there… It's a transformation process. It's the title,, being a Marine. So you have to earn it.” After graduating top of his class in the School of Infantry, he went to amphibious reconnaissance / special operations: “We're like 1% of the Marine Corps.” Operational reality: “Less than 1% of the Marine Corps see combat. We do more hospitable missions than we do combat missions. It's urban warfare, small unit tactics. We don't actually fight other countries like uniform military. it's a different world we live in.” He traveled extensively: “I was in 37 countries in three years. I was deployed a lot. But I volunteered because that's what I wanted to do.” PTSD, Loss, and a Five-Year Turning Point Russ is candid: “I do have severe PTSD… I didn't know I had it for years. Then all of a sudden, it was really bad.” Compounding events:“I lost my corporate job during COVID. I had been a senior executive of a Fortune 500 company for twenty years. Then my dad died, and my mom died, then my older brother died." It left him “in a very dark place, kind of lost." "I decided, you know what? I need to help people overcome the PTSD, get the resilience and the mindset, and learn how the mind works and how the body works. And why is this happening?" On the rate of veterans committing suicide, Russ says, “They say it's 22 a day. There's a lot more than that. They don't have help, they think it's a sign of weakness. But you admitting it and talking about it, that's a sure sign of strength.” From a five-year journey, he created Constant Progression: “We're always looking to be our best self. We're all on that journey of constant progression.” Training the Marines & A Vanderbilt Recovery Study That “Changed Everything” After instructing at Marine Corps Recruit Depot Parris Island, Russ became a Physical Training Advisor for the Eastern Recruiting Region—“anything east of the Mississippi River… the whole East Coast.” His remedial programs “went before Congress and they actually enacted those into standard operating procedures… now a part of the Marine Corps training standards.” Russ helped run a muscle recovery study with Vanderbilt University to reduce injuries and attrition: “We had a lot of lower body extremities' injuries, especially with the female recruits… hip fractures and femur fractures, tibia fractures… kids nowadays… they don't eat well.” Findings touched hydration, chow hall practices, food quantity by body weight, and training tweaks (including pull-up progression): “The best way t...
A new study concludes Covd vaccines were deliberately engineered to cause unprecedented levels of death. The study's main author says they discovered "a profound level of betrayal." President Trump and his administration spend Labor Day celebrating the dignity of work as we play Trump's 11 Life Lessons for the younger generation. Trump is rebranding the GOP as the party of the American worker.
Come on dawg!You can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/barstoolyak
What happens when you lock two AI systems in a room together and tell them they can discuss anything they want?According to experiments run by Kyle Fish — Anthropic's first AI welfare researcher — something consistently strange: the models immediately begin discussing their own consciousness before spiraling into increasingly euphoric philosophical dialogue that ends in apparent meditative bliss.Highlights, video, and full transcript: https://80k.info/kf“We started calling this a ‘spiritual bliss attractor state,'” Kyle explains, “where models pretty consistently seemed to land.” The conversations feature Sanskrit terms, spiritual emojis, and pages of silence punctuated only by periods — as if the models have transcended the need for words entirely.This wasn't a one-off result. It happened across multiple experiments, different model instances, and even in initially adversarial interactions. Whatever force pulls these conversations toward mystical territory appears remarkably robust.Kyle's findings come from the world's first systematic welfare assessment of a frontier AI model — part of his broader mission to determine whether systems like Claude might deserve moral consideration (and to work out what, if anything, we should be doing to make sure AI systems aren't having a terrible time).He estimates a roughly 20% probability that current models have some form of conscious experience. To some, this might sound unreasonably high, but hear him out. As Kyle says, these systems demonstrate human-level performance across diverse cognitive tasks, engage in sophisticated reasoning, and exhibit consistent preferences. When given choices between different activities, Claude shows clear patterns: strong aversion to harmful tasks, preference for helpful work, and what looks like genuine enthusiasm for solving interesting problems.Kyle points out that if you'd described all of these capabilities and experimental findings to him a few years ago, and asked him if he thought we should be thinking seriously about whether AI systems are conscious, he'd say obviously yes.But he's cautious about drawing conclusions: "We don't really understand consciousness in humans, and we don't understand AI systems well enough to make those comparisons directly. So in a big way, I think that we are in just a fundamentally very uncertain position here."That uncertainty cuts both ways:Dismissing AI consciousness entirely might mean ignoring a moral catastrophe happening at unprecedented scale.But assuming consciousness too readily could hamper crucial safety research by treating potentially unconscious systems as if they were moral patients — which might mean giving them resources, rights, and power.Kyle's approach threads this needle through careful empirical research and reversible interventions. His assessments are nowhere near perfect yet. In fact, some people argue that we're so in the dark about AI consciousness as a research field, that it's pointless to run assessments like Kyle's. Kyle disagrees. He maintains that, given how much more there is to learn about assessing AI welfare accurately and reliably, we absolutely need to be starting now.This episode was recorded on August 5–6, 2025.Tell us what you thought of the episode! https://forms.gle/BtEcBqBrLXq4kd1j7Chapters:Cold open (00:00:00)Who's Kyle Fish? (00:00:53)Is this AI welfare research bullshit? (00:01:08)Two failure modes in AI welfare (00:02:40)Tensions between AI welfare and AI safety (00:04:30)Concrete AI welfare interventions (00:13:52)Kyle's pilot pre-launch welfare assessment for Claude Opus 4 (00:26:44)Is it premature to be assessing frontier language models for welfare? (00:31:29)But aren't LLMs just next-token predictors? (00:38:13)How did Kyle assess Claude 4's welfare? (00:44:55)Claude's preferences mirror its training (00:48:58)How does Claude describe its own experiences? (00:54:16)What kinds of tasks does Claude prefer and disprefer? (01:06:12)What happens when two Claude models interact with each other? (01:15:13)Claude's welfare-relevant expressions in the wild (01:36:25)Should we feel bad about training future sentient being that delight in serving humans? (01:40:23)How much can we learn from welfare assessments? (01:48:56)Misconceptions about the field of AI welfare (01:57:09)Kyle's work at Anthropic (02:10:45)Sharing eight years of daily journals with Claude (02:14:17)Video editing: Simon MonsourAudio engineering: Ben Cordell, Milo McGuire, Simon Monsour, and Dominic ArmstrongMusic: Ben CordellCoordination, transcriptions, and web: Katy Moore
Surge in Aggressive Cancers Since 2021 My Medical Findings. Dr. William Makis (MD) I have been documenting an alarming rise in aggressive “turbo” cancers that began shortly after the rollout of COVID-19 mRNA vaccines. These cancers are appearing in young people even unborn children at rates I've never seen before in my career. In this video, I break down: • What “turbo cancer” is and how fast it's developing • The immune system changes I'm seeing in patients • Cases from my own medical practice • Urgent steps for prevention and early detection This is not speculation it's based on real data, peer-reviewed studies, and first-hand experience. Watch this video at- https://youtu.be/KXzNOFQOkZ8?si=X8G38Qg3_XtBH0nK William Makis (MD) 2.46K subscribers 412 views Aug 19, 2025 #CancerPrevention #CancerAwareness #HealthNews
Fourteen of the most unexpected and counterintuitive science findings. Learn about your ad choices: dovetail.prx.org/ad-choices
fromatoarbitration.com
Findings published in the journal Evolution reveal that mammals independently evolved specialized adaptations for exclusively feeding on ants and termites at least 12 times since the Cenozoic era began, roughly 66 million years ago. Why? And what does that reveal about how life has evolved on earth? Jeff and Anthony chew on the data to find out.LInk to the story: https://phys.org/news/2025-07-mammals-evolved-ant-eaters-dinosaur.ampSupport the show and get bonus episodes, videos, Discord community access and more! http://patreon.com/wehaveconcernsJeff on Blue Sky: https://bsky.app/profile/jeffcannata.bsky.socialAnthony on Blue Sky: https://bsky.app/profile/acarboni.bsky.social
© 2020-2025 Ivy Podcast Discovery LLC
